Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8581389 | 0.87 | TK1 (0.59) | TK1POLB | |
| SCHEMBL4022253 | 0.85 | TK1 (0.57) | TK1POLB | |
| SCHEMBL5583976 | 0.84 | TK1 (0.61) | TK1 | |
| SCHEMBL25752530 | 0.84 | TK1 (0.70) | TK1POLB | |
| SCHEMBL6379327 | 0.83 | TK1 (0.67) | TK1 | |
| SCHEMBL7857616 | 0.82 | TK1 (0.42) | TK1 | |
| SCHEMBL6292694 | 0.82 | DUT (0.45) | TK1 | |
| SCHEMBL24420522 | 0.81 | TK1 (0.65) | TK1POLB | |
| SCHEMBL316663 | 0.81 | TK1 (0.65) | TK1POLB | |
| SCHEMBL658884 | 0.81 | TK1 (0.65) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424939-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2669290-A1 | Nucleic Acid Chemical Modifications | Alnylam Pharmaceuticals Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2403863-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090018325-A1 | PROCESS FOR PREPARING L-NUCLEIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | CERCUS JACQUES | 2009-01-15 | — | — | US | disclosed |
| US-5359067-A | Process for the preparation of 5-substituted cytosines and other 4,5-disubstituted pyrimidin-2(1H)-ones, and intermediates arising in the course of this | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-25 | — | — | US | disclosed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | TK1 143/4885POLB 86/4885 |
| US-20090018325-A1 | PROCESS FOR PREPARING L-NUCLEIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | RNGTT, TYMS, TYMP | TK1 28/4885POLB 54/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | TK1 155/4885POLB 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.